Seaport Therapeutics Inc. Common Stock
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company...
Latest News
4 days ago · seekingalpha.com
Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO DiscountSeaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD markets. SPTX maintains a cash runway into 2029, with $427.3 million at June 30, trading at a forward book value discount versus sector peers. Recent clean driving data for GlyphAllo and strong PK data for GlyphAgo de-risk regulatory and commercial pathways ahead of the pivotal BUOY-1 readout.
2 months ago · businesswire.com
Seaport Therapeutics to Participate in September Investor ConferencesBOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Sympo.
2 months ago · businesswire.com
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy VolunteersBOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.
2 months ago · businesswire.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy VolunteersBOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.
2 months ago · 247wallst.com
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPOSeaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.
3 months ago · seekingalpha.com
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of ValidationSeaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's Phase 2b BUOY-1 trial in MDD targets a differentiated profile, with top-line data expected in H1 2027 and a focus on anxious distress subpopulations. GlyphAgo's strong Phase 1 PK data and platform repeatability support SPTX's strategy, with Phase 2a in GAD set for H2 2026 and registration-enabling studies to follow.
3 months ago · businesswire.com
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressBOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SPTX